{"schema_version":"1.0","type":"article","title":"RFK Jr. Clears Peptides, Hims Reruns GLP-1 Play","url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.md","lang":"en","date":"2026-11-04","publish_at":"2026-11-04T08:00:00+08:00","updated_at":"2026-11-04","category":"商業分析系列","topic":"商業分析系列","tags":["peptides","BPC-157","Hims & Hers","compounding","GLP-1"],"summary":"HHS will not enforce against pharmacies compounding BPC-157 and five other unapproved peptides. Hims & Hers opened a waitlist the next day, rerunning its compounded-GLP-1 model. In Taiwan, unlicensed imports remain prohibited drugs.","key_points":["On Oct 28, HHS Secretary Robert F. Kennedy Jr. signed an interim policy pausing enforcement against compounding of six unapproved peptides, including BPC-157 and TB-500; FDA career scientists had advised against listing them.","Hims & Hers previewed Peptides+ on Oct 29, with BPC-157 and TB-500 to follow 'when allowable', seven months after shifting its weight-loss business from compounded semaglutide to Novo Nordisk's branded drugs.","Under Article 22 of Taiwan's Pharmaceutical Affairs Act, drugs imported without approval are prohibited drugs; the US policy has no effect outside the US."],"facts":[{"claim":"HHS 臨時政策簽署日","value":"2026-10-28","unit":"日期","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"聯邦公報刊登日","value":"2026-10-30","unit":"日期","as_of":"2026-10-30","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"政策涵蓋胜肽數","value":"6","unit":"種","as_of":"2026-10-30","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"政策條件數","value":"10","unit":"條","as_of":"2026-10-30","source":"Peptides: HHS Announces Limited Enforcement Discretion｜Foley & Lardner"},{"claim":"公眾意見截止日","value":"2026-11-13","unit":"日期","as_of":"2026-10-30","source":"Peptides: HHS Announces Limited Enforcement Discretion｜Foley & Lardner"},{"claim":"顧問委員會明年再審胜肽數（2 月）","value":"5","unit":"種","as_of":"2026-10-29","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"7 月會議前 FDA 新任命委員","value":"8","unit":"名","as_of":"2026-10-29","source":"HHS will permit compounding of six peptides ahead of formal rulemaking｜RAPS"},{"claim":"遠距醫療網站胜肽月費","value":"199–249","unit":"美元／月","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"胜肽市場分析師估計","value":"33","unit":"億美元","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"Hims Peptides+ 預覽公布日","value":"2026-10-29","unit":"日期","as_of":"2026-10-29","source":"Expanding Safe Access to Peptides｜Hims & Hers Newsroom"},{"claim":"Hims 轉向原廠 GLP-1 宣布日","value":"2026-03-09","unit":"日期","as_of":"2026-03-09","source":"Hims & Hers Announces Strategic Shift for US Weight Loss Business｜Hims & Hers IR"},{"claim":"Hims 進入美國減重市場年份","value":"2023","unit":"年","as_of":"2026-03-09","source":"Hims & Hers Announces Strategic Shift for US Weight Loss Business｜Hims & Hers IR"},{"claim":"Hims 第三季財報日","value":"2026-11-09","unit":"日期","as_of":"2026-10-12","source":"Hims & Hers to Announce Third Quarter 2026 Financial Results｜Hims & Hers IR"},{"claim":"BPC-157 人體研究","value":"3 個無對照試驗，合計 30","unit":"人","as_of":"2026-07-01","source":"Heal or Harm? BPC-157 in the Gray Zone｜Pharmacy Times"},{"claim":"WADA 禁用 BPC-157 年份","value":"2022","unit":"年","as_of":"2026-07-01","source":"Heal or Harm? BPC-157 in the Gray Zone｜Pharmacy Times"},{"claim":"台灣減重 LINE 群組成員","value":"2,000+","unit":"人","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"Mounjaro 台灣灰市轉手價","value":"9,500–15,000","unit":"新台幣","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"食藥署 2024 年起稽查藥局診所","value":"487","unit":"家","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"稽查違規家數","value":"85","unit":"家","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"稽查罰款","value":"260","unit":"萬新台幣","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"藥事法第 82 條禁藥輸入最重刑","value":"10 年徒刑、1 億元罰金","unit":"—","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"}],"sections":["01｜What was actually granted: a promise not to enforce","02｜Hims is lining up for the same model it used with GLP-1s","03｜The FDA's own scientists said no","04｜Taiwan: without a license, it is a prohibited drug","05｜Six peptides, one new sales channel","References"],"references":[{"title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances","source":"Federal Register (HHS","date":"2026-10-30","url":"https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances"},{"title":"July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee","source":"U.S. FDA","date":"2026-07-23","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"},{"title":"5 Things to Know About HHS's Interim Peptide Compounding Policy","source":"AJMC","date":"2026-10-29","url":"https://www.ajmc.com/view/5-things-to-know-about-hhs-s-interim-peptide-compounding-policy"},{"title":"HHS will permit compounding of six peptides ahead of formal rulemaking","source":"RAPS Regulatory Focus","date":"2026-10-29","url":"https://www.raps.org/resource/hhs-will-permit-compounding-of-six-peptides-ahead-of-formal-rulemaking.html"},{"title":"Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides","source":"Foley & Lardner","date":"2026-10-30","url":"https://www.foley.com/insights/publications/2026/10/peptides-hhs-announces-limited-enforcement-discretion-for-compounding-of-six-peptides/"},{"title":"The Peptide Rush Has Begun","source":"TIME","date":"2026-10-28","url":"https://time.com/article/2026/10/28/peptide-rush-has-begun/"},{"title":"Starting Today, These Six Peptides Are Back","source":"Dr. Jesse Morse Substack","date":"2026-10-30","url":"https://drjessemorse.substack.com/p/starting-today-these-six-peptides"},{"title":"Expanding Safe Access to Peptides","source":"Hims & Hers Newsroom","date":"2026-10-29","url":"https://news.hims.com/newsroom/expanding-safe-access-to-peptides"},{"title":"Hims & Hers Announces Strategic Shift for US Weight Loss Business","source":"Hims & Hers IR","date":"2026-03-09","url":"https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx"},{"title":"Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026","source":"Hims & Hers IR","date":"2026-10-12","url":"https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Third-Quarter-2026-Financial-Results-on-November-9-2026/default.aspx"},{"title":"Heal or Harm? Body Protective Compound-157 in the Gray Zone","source":"Pharmacy Times","date":"2026-07-01","url":"https://pharmacytimes.com/view/heal-or-harm-body-protective-compound-157-in-the-gray-zone"},{"title":"Illicit distribution of GLP-1/GIP drugs in Taiwan (社群販售、藥局私賣、日本代購","source":"The Reporter","date":"2026-01-19","url":"https://www.twreporter.org/a/illicit-drug-distribution-of-glp-1-gip-in-taiwan-1"}],"images":[{"alt":"Fig. 1｜From banned to tolerated: a year in the life of six peptides","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/figure-01.png"},{"alt":"Fig. 2｜How the peptide business runs: the compounded-GLP-1 route","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/figure-02.png"},{"alt":"Fig. 3｜How thin is the evidence? The case of BPC-157","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/figure-03.png"},{"alt":"Fig. 4｜The same vial in the US and in Taiwan","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-04）。RFK Jr. Clears Peptides, Hims Reruns GLP-1 Play。https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","ai_question":"What changed for On Oct 28?"}